Prophylactic HPV vaccines

摘要

The ability to generate human papillo-mavirus (HPV) virus-like particles (VLPs) by the synthesis and self-assembly in vitro of the major virus capsid protein L1 has transformed our prospects for preventing both benign and malignant HPV-associated genital disease and, in particular, for significantly reducing the incidence of cervical carcinoma in women. Two HPV L1 VLP vaccines have been developed. Both of these vaccines have been shown to be safe and highly immunogenic, generating high titres of neutralising antibody that persist at measurable levels higher than those measured in natural infections for at least 60 months post-vaccination.